Moleculin Biotech Inc MBRX
News
-
Moleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial
-
Moleculin Announces Reverse Stock Split
-
Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit
-
Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout
-
Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine
-
Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR
-
Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040
-
Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings
Trading Information
- Previous Close Price
- $5.89
- Day Range
- $5.65–6.59
- 52-Week Range
- $3.23–315.00
- Bid/Ask
- $6.54 / $6.82
- Shares Outstanding
- 1.02M
- Market Cap
- $6.63M
- Volume/Avg
- 27,667 / 68,335
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 17
- Website
- https://www.moleculin.com
Valuation
|
Metric
|
MBRX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.20 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
MBRX
|
|---|---|
Quick Ratio | 0.78 |
Current Ratio | 0.94 |
Interest Coverage | — |
Quick Ratio
MBRX
Profitability
|
Metric
|
MBRX
|
|---|---|
Return on Assets (Normalized) | −294.41% |
Return on Equity (Normalized) | −4,154.14% |
Return on Invested Capital (Normalized) | −3,371.18% |
Return on Assets
MBRX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|bK?Zgs% | LOCK|zT?DJ | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|<%VkQB | LOCK|q^g! | $83B | |||
| Moderna Inc
MRNA
| LOCK|v?N>&!Z | LOCK|bH> | $80B | |||
| argenx SE ADR
ARGX
| LOCK|n$!v&vS | LOCK|vkb | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|X@TYZNd | LOCK|HF^ | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|^<>R#F | LOCK|SDMW | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|?F!>sn> | LOCK|y%#l% | $28B | |||
| Incyte Corp
INCY
| LOCK|vyk^Jw | LOCK|&@ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|d$wRGw | LOCK|<< | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|^kpV<! | LOCK|t#F | $14B |
United States